Eli Lilly delivered 48% Q2 revenue growth and raised full-year guidance, but the stock already prices in a lot of that momentum. Hold reflects strong execution, a deep pipeline, and a premium valuation that limits upside.
Eli Lilly (LLY) is a high-quality growth company priced for continued execution. Q2 2026 revenue reached $22.97B, up 48.0% year over year, while non-GAAP EPS rose 33.0% to $8.38. Management also raised 2026 revenue guidance to $85.0B-$87.0B and increased performance margin guidance to 49.0%-50.5%. Those results support a strong operating thesis.
The stock price of $1,246.89 already reflects much of that success. LLY trades at 42.9x trailing earnings, 35.2x forward earnings, 14.9x enterprise value to revenue, and 1.6x PEG. The growth is real, but the valuation leaves less room for execution errors, pricing pressure, or slower adoption of new products.
The balanced conclusion is Hold for a moderate-risk investor with a medium-term horizon. Mounjaro, Zepbound, Foundayo, retatrutide, manufacturing expansion, and a broad pipeline provide substantial growth support. Debt of $42.5B at the end of 2025, Q2 debt of $54.9B, a 2.2% free-cash-flow yield in the valuation snapshot, and a premium multiple temper the upside.
Eli Lilly and Company is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis. The company employs approximately 50,000 people and trades on the NYSE under LLY. David A. Ricks serves as chairman, president, and chief executive officer.
Lilly discovers, develops, manufactures, and markets prescription medicines across the United States, Europe, China, Japan, and other international markets. Its portfolio covers cardiometabolic health, oncology, immunology, neuroscience, diabetes, and migraine prevention.
The business has shifted toward product revenue as its medicines scale. Product revenue reached $61.0B in 2025, or 93.5% of total revenue, compared with 84.4% in 2023. Collaboration and other revenue contributed $4.2B in 2025, or 6.5% of total revenue.
Lilly's commercial engine is now centered on incretin medicines, but the company is building a broader platform. In Q2 2026, oncology, immunology, and neuroscience key products grew 121.0% year over year, providing evidence that the investment case extends beyond one therapeutic category.
Lilly reports its business primarily through products, therapeutic areas, and geographies rather than a classic segment structure. The product portfolio generated $15.7B of key-product revenue in Q2 2026, up 76.0% year over year.
Cardiometabolic Health is the dominant growth area. Mounjaro generated $9.9B in Q2 sales, up 91.0%, while Zepbound generated $4.9B, up 46.0%. Foundayo contributed $98M during its early commercial phase. Together, Mounjaro and Zepbound generated $14.9B and added $6.3B of year-over-year growth.
Immunology is gaining scale through Ebglyss, which generated $201M in Q2 sales, up 131.0%. Oncology products include Jaypirca, with Q2 sales of $192M and growth of 56.0%, and Inluriyo, which generated $75M. Neuroscience contributed Kisunla sales of $167M.
Geographic growth is broad. Q2 revenue totaled $14.41B in the United States, $4.12B in Europe, $628M in Japan, $941M in China, and $2.88B in the rest of the world. Constant-currency growth ranged from 30.0% in Japan to 136.0% in the rest of the world.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Mounjaro and Zepbound are the central assets in the LLY thesis. Both contain tirzepatide, but Mounjaro serves type 2 diabetes while Zepbound serves chronic weight management. Their combined Q2 revenue of $14.9B represented approximately two-thirds of quarterly revenue.
The volume profile is powerful. Worldwide revenue increased 48.0% in Q2 because volume rose 60.0%, partly offset by a 13.0% decrease in realized prices. In the United States, revenue grew 33.0%, driven mainly by Mounjaro and Zepbound volume.
Foundayo adds a different form of optionality. It is an oral small-molecule incretin, which gives Lilly a way to address patients who prefer a daily tablet over an injection. Lilly completed its U.S. submission for type 2 diabetes, received obesity approval in the UAE and Saudi Arabia, and received approval in Mexico for obesity and type 2 diabetes.
The early commercial numbers are modest relative to the established franchise, but the launch infrastructure is expanding. Lilly secured access across all three major U.S. PBMs in June, began broad direct-to-consumer promotion, and reported that Foundayo volume nearly doubled over a month by the last week of July.
Lilly's competitive advantage combines clinical efficacy, commercial scale, manufacturing investment, and a deep development pipeline. More than 40 active Phase 3 programs demonstrate the size of the current research effort, while acquisitions have added assets in neuroscience, hematology, infectious disease, and genetic medicine.
Retatrutide is the most important next-generation asset. Lilly reported positive results from the TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 Phase 3 trials, with data covering obesity, type 2 diabetes, cardiovascular disease, sleep apnea, and knee osteoarthritis pain. Lilly plans a U.S. BLA submission in Q1 2027.
The pipeline also includes orforglipron, insulin efsitora alfa, and VERVE-102. In ACHIEVE-3, orforglipron delivered superior glycemic control and weight reduction compared with 7 mg and 14 mg oral semaglutide. Insulin efsitora alfa achieved A1C reductions comparable with once-daily basal insulin in Phase 3 testing.
Outside cardiometabolic health, the pipeline is producing meaningful clinical signals. Selpercatinib reduced the risk of disease recurrence or death by 83.0% in the LIBRETTO-432 Phase 3 trial, while adding pirtobrutinib to a fixed-duration regimen reduced the risk of progression or death by 45.0% in previously treated CLL.
Manufacturing capacity is a strategic requirement for Lilly because demand for injectable incretins has grown faster than traditional pharmaceutical supply systems. Lilly opened its first dedicated genetic medicine manufacturing facility in Lebanon, Indiana, and produced the first commercial material at its Limerick, Ireland facility.
In August 2026, Lilly announced an additional $4.5B commitment to expand Indiana manufacturing sites. The 2025 financial statements show capital expenditures of $7.8B, up from $1.9B in 2021, confirming that capacity expansion is absorbing substantial capital.
The spending is already showing up in production economics. Q2 non-GAAP gross margin reached 86.3%, up 1.3 percentage points from the prior year, driven by favorable product mix and lower production costs. This is an important operating advantage as Lilly moves more volume through its network.
The pharmaceutical market provides a large backdrop, but Lilly's most valuable opportunity is the cardiometabolic market. Mordor Intelligence estimates the global pharmaceutical market at $1.89T in 2026, reaching $2.62T by 2031 at a 6.7% compound annual growth rate.
Lilly's own investor materials identify more than 170 million potential U.S. patients by 2030 across obesity or overweight with an obesity-related comorbidity and type 2 diabetes. The same materials estimate an outside-the-U.S. addressable market of approximately 1 billion people.
The Q2 market data confirms that the category is still expanding. U.S. obesity incretin prescriptions grew 78.0% year over year, while the U.S. type 2 diabetes incretin market grew 9.0%. International incretin sales grew 74.0%, and Lilly held approximately 55.0% of that market after gaining nearly 2 percentage points from Q1.
The next phase of competition will focus on oral delivery, broader indications, lower production costs, and payer access. Foundayo and retatrutide position Lilly across those four dimensions, although each asset still requires successful commercialization and reimbursement execution.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Lilly sells through a multi-layered healthcare system that includes patients, physicians, pharmacies, pharmacy benefit managers, employers, government programs, and national health services. Product adoption depends on clinical outcomes, physician confidence, insurance coverage, affordability, and reliable supply.
Obesity customers show a particularly important self-pay component. Approximately 45.0% of total Zepbound prescriptions and 55.0% of new Zepbound prescriptions were self-pay in Q2. That mix supports demand but also exposes revenue to consumer affordability and price sensitivity.
The Medicare GLP-1 Bridge program launched on July 1 and extended obesity GLP-1 coverage to approximately 20 million eligible Americans at an out-of-pocket cost of $50 per month. Lilly reported that the program increased coverage for its U.S. obesity medicines by 35.0%.
Physician and patient convenience also matter. Ebglyss received approval for maintenance dosing once every eight weeks, and Lilly is exploring once-every-12-weeks dosing with its partner Almirall. Orforglipron addresses a separate convenience preference through oral daily delivery.
Novo Nordisk is Lilly's primary direct competitor in obesity and diabetes through Wegovy and Ozempic. The two companies compete on weight reduction, glucose control, tolerability, convenience, supply, price, and payer coverage. Lilly's Q2 share data gives it a strong current position, with approximately six out of ten U.S. obesity incretin prescriptions and seven out of ten injectable obesity prescriptions going to Lilly medicines.
Competition is broader in other therapeutic areas. Merck remains a major oncology competitor through Keytruda and Welireg. Roche, Pfizer, AstraZeneca, Novartis, Sanofi, Amgen, and AbbVie compete with Lilly across oncology, immunology, cardiovascular medicine, and specialty care.
Lilly's advantage is not limited to an individual product. It has a commercial footprint, a growing manufacturing network, LillyDirect access infrastructure, more than 40 active Phase 3 programs, and a record of acquiring assets such as Centessa, Ajax, Kelonia, and AtaiBeckley.
The main competitive risk is that a rival product offers better efficacy, tolerability, convenience, availability, or cost-effectiveness. The 13.0% worldwide decline in realized prices during Q2 shows that volume leadership does not eliminate pricing pressure.
For Lilly, healthcare policy is more important than conventional economic cyclicality. In Q2, U.S. price declined 3.0%, and management said the decline would have been 9.0% excluding changes to rebate and discount estimates. Worldwide realized prices declined 13.0% while volume increased 60.0%.
Government reimbursement can expand the patient base while reducing net pricing. Lilly's 2025 preliminary agreements with the U.S. government included lower Medicaid and certain other drug prices, making access gains and price concessions two sides of the same policy equation.
International policy remains an opportunity and a constraint. Mounjaro's inclusion on China's National Reimbursement Drug List supported 93.0% constant-currency revenue growth in China. Mounjaro is also reimbursed for type 2 diabetes and obesity in France. Those events show how reimbursement decisions can alter geographic growth quickly.
The broader market is also shifting toward biologics, digital access, and data-driven drug development. Mordor Intelligence estimates Asia-Pacific pharmaceutical growth at 8.9% annually through 2031, while Gartner forecasts life-science IT spending growth of 9.3% in 2025. Lilly's international footprint and LillyDirect platform align with both trends.
Debt rose to $54.9B in Q2 2026 after ending 2025 at $42.5B, leaving leverage and a 2.2% free-cash-flow yield as key constraints on the bullish case.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 2026 revenue jumped 48.0% to $22.97B while non-GAAP EPS climbed 33.0% to $8.38, with Mounjaro and Zepbound doing most of the heavy lifting.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management raised 2026 revenue guidance to $85.0B-$87.0B and performance margin guidance to 49.0%-50.5%, signaling continued momentum into the back half of the year.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At 42.9x trailing earnings, 35.2x forward earnings, 14.9x EV/revenue, and a 1.6x PEG, Lilly trades at a premium that leaves little margin for error.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s fair value sits at $1,300, below the current $1,246.89 share price only modestly in valuation terms but enough to support a Hold stance.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Eli Lilly has built one of the strongest growth platforms in large-cap pharmaceuticals. Q2 revenue of $22.97B, Mounjaro and Zepbound sales of $14.9B, a 54.8% non-GAAP performance margin, and raised 2026 guidance show an enterprise operating at exceptional speed.
The investment case rests on more than current demand. Manufacturing capacity is expanding, Foundayo is broadening the oral product opportunity, retatrutide has produced positive Phase 3 data, and oncology, immunology, and neuroscience products grew 121.0% in Q2. Those facts support continued business growth beyond the current blockbuster cycle.
The counterweight is valuation. A 42.9x trailing P/E, $54.9B of Q2 debt, a 13.0% worldwide realized-price decline, and intense competition make the stock less forgiving than the business. At $1,246.89, LLY earns a Hold rather than a Buy. A lower entry price would improve the risk-reward balance without requiring a change to the long-term growth thesis.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Eli Lilly and Company (LLY) rises after a strong earnings-driven repricing tied to its obesity franchise, Q2 beat, and higher 2026 guidance. The stock moved above its listed 52-week high as investors focused on Mounjaro, Zepbound, and continued growth momentum. Volume data does not confirm a breakout.
Eli Lilly is still one of the strongest growth stories in large-cap pharma, powered by tirzepatide and an expanding cardiometabolic pipeline. The stock remains constructive, but valuation now demands continued execution rather than multiple expansion.
Eli Lilly's next move looks less like a pipeline trade and more like an access trade. Demand was never the problem; broader PBM coverage and expected Medicare access starting July 1 make the revenue conversion story more immediate.